Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings
Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-05-07 | English | |
| 8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-05-07 | English | |
| ARS - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-04-23 | English | |
| DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-04-23 | English | |
| 8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-03-24 | English | |
| 4 - AMYLYX PHARMACEUTICALS, INC. (0001658551) (Filer) | 2026-03-04 | English |
Browse filings by year
12 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Entrada Therapeutics, Inc.
Clinical-stage biopharma developing EEV-based therapies for…
|
TRDA | US | Manufacturing |
|
Enwei Pharmaceutical Co., Ltd.
Produces Chinese patent medicines and chemical drugs for gy…
|
301331 | CN | Manufacturing |
|
ENZYCHEM LIFESCIENCES CORPORATION
Develops small molecule therapeutics for cancer, inflammati…
|
183490 | KR | Manufacturing |
|
Enzymatica AB
Develops medical devices for infections based on a propriet…
|
ENZY | SE | Manufacturing |
|
Epitomee Medical Ltd.
Develops ingestible therapeutic devices for chronic disease…
|
EPIT | IL | Manufacturing |
|
EPSILON HEALTHCARE LIMITED
Integrated medicinal cannabis company providing manufacturi…
|
EPN | AU | Manufacturing |
|
EQL Pharma AB
Develops and sells niche generic and specialty medicines, p…
|
EQL | SE | Manufacturing |
|
Erasca, Inc.
A clinical-stage oncology company developing therapies for …
|
ERAS | US | Manufacturing |
|
Eris Lifesciences Limited
Develops and markets branded generic pharmaceuticals for ch…
|
ERIS | IN | Manufacturing |
|
Ernexa Therapeutics Inc.
Biopharmaceutical company developing cell therapies for can…
|
ERNA | US | Manufacturing |
Amylyx Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31865/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31865 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31865 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31865 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31865}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Amylyx Pharmaceuticals, Inc. (id: 31865)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.